News Archive

June 2018

• Press Release Jun 26, 2018

  Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin

  Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also…
• Press Release Jun 18, 2018

  Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery

  Better visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1]  Detailed findings presented at World Ophthalmology Congress 2018…
• Press Release Jun 16, 2018

  Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

  Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable[1]  Patients had a 65% chance of being…
• Press Release Jun 15, 2018

  Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

  Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of…
• Press Release Jun 15, 2018

  Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer

  Comparison of Jakavi® (ruxolitinib) vs. best available therapy presented at EHA suggests reduced risk of death in patients with inadequately controlled polycythemia vera (PV)[1]   Additional…
• Press Release Jun 15, 2018

  Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis

  Zessly® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly[1] Switching from the…
• Press Release Jun 13, 2018

  Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis

  26 abstracts on Cosentyx® (secukinumab) in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) will be presented at the Annual European Congress of Rheumatology (EULAR 2018)[1]…
• Press Release Jun 07, 2018

  Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs

  Patients reported prolonged maintenance of global health status[1](overall health) Longer time to deterioration (TTD) seen across multiple clinically relevant symptom categories including…
• Press Release Jun 06, 2018

  Novartis Schullabor empfängt hunderttausendsten Besucher

  Basel, 6. Juni, 2018 - Mit dem heutigen Besuch einer Schulklasse des Gymnasiums am Münsterplatz in Basel hat das Novartis Schullabor die magische Zahl von über 100'000 Besucherinnen und Besuchern…
• Press Release Jun 03, 2018

  Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

  Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line…
• Press Release Jun 02, 2018

  New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

  ENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna®   Findings further support durability and…
• Ad-hoc Releases Jun 01, 2018

  Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion

  Basel, June 1, 2018 - Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV)…